Blockade of programmed death-1 (PD-1) or programmed death ligand-1 (PD-L1) has become a new immunotherapy and achieved exciting results in some types of cancer, such as melanoma [4], nonsmall cell lung cancer [5], and hepatocellular carcinoma [6]. Here, CD274 is linked to cancer.